Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | YAP1 | P46937 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18921646 | 0.86 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL2386800 | 0.86 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL26925080 | 0.84 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL28568843 | 0.84 | MEN1 (0.47) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL23249942 | 0.83 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL29132380 | 0.83 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL30981203 | 0.82 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL26924756 | 0.82 | SMN1; SMN2 (0.49) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL27242967 | 0.82 | SMN1; SMN2 (0.49) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL26925229 | 0.82 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | ARVINAS OPERATIONS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4655073-A2 | CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO | Arvinas Operations, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12448399-B2 | Cereblon-based KRAS degrading PROTACs and uses related thereto | ARVINAS OPERATIONS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| WO-2024159164-A2 | CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO | ARVINAS OPERATIONS, INC. (US) | 2024-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448399-B2 | Cereblon-based KRAS degrading PROTACs and uses related thereto | CRBN, KRAS, WEE1 | SMN1; SMN2 3957/4885NPC1 4286/4885RAB9A 609/4885 |
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | KRAS, CRBN, HRAS | SMN1; SMN2 3271/4885NPC1 2586/4885RAB9A 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.